Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 1201 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
+ 655 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
+ 563 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
+ 187 more sites in the U.S.
Phase 3 Recruiting Industry
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…
Sponsor: AbbVie
NCT ID: NCT05445778
Locations: - Usa Mitchell Cancer Institute /ID# 269661 — Mobile, Alabama
- Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987 — Phoenix, Arizona
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573 — Irvine, California
+ 71 more sites in the U.S.
Phase 3 Recruiting Network
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…
Sponsor: GOG Foundation
NCT ID: NCT05659381
Locations: - City of Hope — Duarte, California
- University of California San Diego Moores Cancer Center — La Jolla, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
+ 56 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Locations: - Alaska Women's Cancer Care — Anchorage, Alaska
- Yale University School of Medicine — New Haven, Connecticut
- Sylvester Comprehensive Cancer Center at Lennar — Coral Gables, Florida
+ 40 more sites in the U.S.
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Locations: - HonorHealth — Phoenix, Arizona
- University of Arkansas — Little Rock, Arkansas
- UCLA Health — Los Angeles, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Industry
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…
Sponsor: Genelux Corporation
NCT ID: NCT05281471
Locations: - The University of South Alabama, Mitchell Cancer Institute — Mobile, Alabama
- University of Arizona Cancer Center — Tucson, Arizona
- City of Hope — Duarte, California
+ 28 more sites in the U.S.
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Locations: - University of Alabama at Birmingham ( Site 0006) — Birmingham, Alabama
- Alaska Women's Cancer Care ( Site 0096) — Anchorage, Alaska
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) — New Haven, Connecticut
+ 27 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Locations: - Alaska Womens Cancer Care Akwcc — Anchorage, Alaska
- City of Hope Medical Center — Duarte, California
- Valkyrie Clinical Trials — Los Angeles, California
+ 23 more sites in the U.S.
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…
Sponsor: AstraZeneca
NCT ID: NCT07218809
Locations: - Research Site — Fort Lauderdale, Florida
- Research Site — Jupiter, Florida
- Research Site — Evanston, Illinois
+ 14 more sites in the U.S.